164 related articles for article (PubMed ID: 15119918)
1. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen TJ; Iosifescu DV; Summergrad P; Sklarsky KG; Alpert JE; Nierenberg AA; Fava M
J Clin Psychiatry; 2004 Apr; 65(4):543-6. PubMed ID: 15119918
[TBL] [Abstract][Full Text] [Related]
2. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine.
Denninger JW; Papakostas GI; Mahal Y; Merens W; Alpert JE; Nierenberg AA; Yeung A; Fava M
Psychosomatics; 2006; 47(4):348-52. PubMed ID: 16844895
[TBL] [Abstract][Full Text] [Related]
3. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
4. Residual symptoms in depressed patients who respond acutely to fluoxetine.
Nierenberg AA; Keefe BR; Leslie VC; Alpert JE; Pava JA; Worthington JJ; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Apr; 60(4):221-5. PubMed ID: 10221281
[TBL] [Abstract][Full Text] [Related]
5. Timing of onset of antidepressant response with fluoxetine treatment.
Nierenberg AA; Farabaugh AH; Alpert JE; Gordon J; Worthington JJ; Rosenbaum JF; Fava M
Am J Psychiatry; 2000 Sep; 157(9):1423-8. PubMed ID: 10964858
[TBL] [Abstract][Full Text] [Related]
6. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
Papakostas GI; Petersen T; Sklarsky KG; Nierenberg AA; Alpert JE; Fava M
Psychiatry Res; 2007 Jan; 149(1-3):195-200. PubMed ID: 17157390
[TBL] [Abstract][Full Text] [Related]
7. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
Papakostas GI; Petersen T; Hughes ME; Nierenberg AA; Alpert JE; Fava M
Psychiatry Res; 2004 May; 126(3):287-90. PubMed ID: 15157754
[TBL] [Abstract][Full Text] [Related]
8. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy.
Papakostas GI; Petersen T; Mischoulon D; Green CH; Nierenberg AA; Bottiglieri T; Rosenbaum JF; Alpert JE; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1096-8. PubMed ID: 15323595
[TBL] [Abstract][Full Text] [Related]
9. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.
Papakostas GI; Petersen T; Mischoulon D; Ryan JL; Nierenberg AA; Bottiglieri T; Rosenbaum JF; Alpert JE; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1090-5. PubMed ID: 15323594
[TBL] [Abstract][Full Text] [Related]
10. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.
Judd LL; Rapaport MH; Yonkers KA; Rush AJ; Frank E; Thase ME; Kupfer DJ; Plewes JM; Schettler PJ; Tollefson G
Am J Psychiatry; 2004 Oct; 161(10):1864-71. PubMed ID: 15465984
[TBL] [Abstract][Full Text] [Related]
11. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder.
Suri RA; Altshuler LL; Rasgon NL; Calcagno JL; Frye MA; Gitlin MJ; Hwang S; Zuckerbrow-Miller J
J Clin Psychiatry; 2000 Dec; 61(12):942-6. PubMed ID: 11206600
[TBL] [Abstract][Full Text] [Related]
13. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.
Thase ME; Blomgren SL; Birkett MA; Apter JT; Tepner RG
J Clin Psychiatry; 1997 Jan; 58(1):16-21. PubMed ID: 9055832
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial.
Han C; Pae CU; Lee BH; Ko YH; Masand PS; Patkar AA; Jung IK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):437-44. PubMed ID: 17950970
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
Costa e Silva J
J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263
[TBL] [Abstract][Full Text] [Related]
16. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
Nelson JC; Portera L; Leon AC
J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
18. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
[TBL] [Abstract][Full Text] [Related]
19. Hypochondriacal concerns in depressed outpatients.
Demopulos C; Fava M; McLean NE; Alpert JE; Nierenberg AA; Rosenbaum JF
Psychosom Med; 1996; 58(4):314-20. PubMed ID: 8827793
[TBL] [Abstract][Full Text] [Related]
20. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group.
Small GW; Hamilton SH; Bystritsky A; Meyers BS; Nemeroff CB
Int Psychogeriatr; 1995; 7 Suppl():41-53. PubMed ID: 8580391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
